Integra to acquire SIA for up to $140M; plans $150M share buyback

INTEGRA LIFESCIENCES HOLDINGS CORP

Integra buys SIA for $50M at closing plus up to $90M in milestones; deal expected to close by end of 2022.
SIA 2022E revenue ~$5M; gross margin >75%. Acquisition dilutive ~$0.06 in Year 1, accretive in Year 3.
ROIC expected to exceed 10% by Year 5 (2027).
Plans $150M share repurchase starting early 2023 to largely offset Year 1 dilution.
No FDA-approved surgical matrices for IBBR; Integra's SurgiMend PMA under review, DuraSorb IDE ~70% enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.